Obesity in early adulthood is associated with increased risk for venous thromboembolism later in life, especially pulmonary embolism.
It may be important to sequence
ETV6in patients with inherited thrombocytopenia or malignancy and to schedule regular follow-ups to check for secondary cancers.
Replacing DOACs with alternative parenteral antithrombotic strategies may help to prevent bleeding complications in patients with SARS-CoV-2 infection.
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
Longer duration of AC treatment linked to reduced risk for mortality in hospitalized patients.
Investigators compared the use of DOACs with traditional therapies in patients with acute VTE who were either discharged directly from the ED or hospitalized.
Investigators assessed rates of VTE and arterial thrombotic complications in patients admitted to the ICU with COVID-19 infection.
Case fatality rates may vary among cancer patients with VTE or major bleeding who receive anticoagulant treatments.
Concomitant use of dabigatran with verapamil or diltiazem was found to be associated with an increased risk of bleeding in patients with normal kidney function, according to the findings of a recently published retrospective cohort study.
Splenectomy may be a safe therapeutic options for children with nonmalignant hematologic diseases who have proper vaccinations and follow-up care.
Oral apixaban is noninferior to subcutaneous dalteparin for the treatment of cancer-linked VTE without increasing the risk of major bleeding.
Apixaban or rivaroxaban may be as safe and effective at treating upper extremity deep vein thrombosis as low molecular weight heparin and warfarin.
Prophylactic anticoagulation protocol improves patient outcomes.
Patients with idiopathic thrombocytopenic purpura may have a higher risk of systemic lupus erythematosus and should be monitored for incidental lupus.
Rivaroxaban superior to enoxaparin for preventing major VTE after nonmajor orthopedic surgery.
Compared with controls, the experimental mouse model group was less susceptible to arterial thrombosis in settings using ferric chloride and laser injury–induced thrombosis.
High or intermediate PE risk status was linked with lower rates of DVT, but asymptomatic DVT was more often found with high or intermediate PE risk.
The authors stated, however, that genetic screening should be used with caution in children.
The primary end point of increased platelet count was achieved by 13 of 18 patients with severe refractory immune thrombocytopenia.
This study investigated differences in the morbidity and mortality of patients presenting with PV or ET with and without splanchnic vein thrombosis.
Although 76% of patients reported experiencing complications during treatment, the mortality rate per episode was only 3.7%.
Younger age, male sex, and African American ethnicity were found to be independent predictors of in-hospital mortality in younger patients with TTP.
Thromboprophylaxis with a low-dose direct-acting oral anticoagulant was associated with lower incidences of cancer-associated thrombosis and bleeding compared with placebo.
Severe thrombocytopenia, antithrombin levels, and degree of fibrinogen degradation product elevation were found to be distinguishing factors of aTTP.
Fatigue, emotional and behavioral symptoms, and executive functioning were found to be associated with quality of life but not with bleeding severity and platelet count.
Researchers developed a risk score to assess risk for vitamin K antagonist-associated bleeding events in patients with venous thromboembolism.
In multivariate analysis, history of atrial fibrillation and smoking were associated with risk for thrombosis in patients newly diagnosed with immune thrombocytopenia.
More than half of evaluable patients who received eltrombopag and pulsed dexamethasone achieved the study’s primary end point.
Currently, splenomegaly is not included as a prognostic factor in major prognostic models of Philadelphia-negative myeloproliferative neoplasms.
Researchers assessed the efficacy of rivaroxaban in comparison with other standard anticoagulants in children with acute venous thromboembolism.
Morning or evening administration makes no difference on time outside target INR range
Researchers compared the incidence of venous thromboembolism between children with peripherally inserted central catheters and children with tunneled lines.
The FDA has granted Fast Track designation to bomedemstat (IMG-7289; Imago BioSciences) for the treatment of essential thrombocythemia, a myeloproliferative disorder characterized by high platelet counts.
Elderly patients with immune thrombotic thrombocytopenia purpura often have atypical presentation, which can delay diagnosis and treatment.
The FDA has granted Orphan Drug designation to avatrombopag for the potential treatment of chemotherapy-induced thrombocytopenia, a complication that may lead to chemotherapy dose delays and regimen changes.
Significantly higher odds seen for all four components of MetS, with largest risk increase for hyperlipidemia
Researchers reviewed the diagnosis and management of several pregnancy-specific causes of thrombocytopenia.
Of patients with ADAMTS13 deficiency, those who had type O blood underwent fewer therapeutic plasma exchange procedures compared with patients with type A or B blood.
Researchers evaluated the safety and efficacy of open-label caplacizumab in patients who experienced disease exacerbation during blinded treatment.
C-reactive protein and urine albumin/creatinine ratio were associated with increased risk of bleeding in patients with thrombocytopenia due to hematologic malignancy.
Adding aspirin to direct-acting oral anticoagulant therapy without a clear indication may increase bleeding risk without decreasing thrombotic risk.
Of patients receiving eltrombopag, 78.9% reached platelet count targets, compared with 61.1% of patients receiving intravenous immunoglobulin.
Most individual pharmacokinetic parameter values fell within the expected range irrespective of dosage, VTE outcome, and bleeding events.
Patients treated with rituximab experienced improved relapse-free survival at 1 and 3 years but not 5 years after treatment compared with patients receiving corticosteroids alone.
Researchers assessed clinical outcomes with apixaban, low-molecular-weight heparin, and warfarin to treat venous thromboembolism in patients with cancer.
Patients who were older than 65 years, female, or hospitalized in the northeastern United States experienced increased incidence of intracranial hemorrhage.
Vitamin K antagonist treatment was found to decrease splanchnic vein thrombosis recurrence in patients with myeloproliferative neoplasms.
Researchers found no significant difference in venous thromboembolism recurrence rates between patients with and without autoimmune disorders.
Risk for venous thromboembolism was increased more than 2-fold for men with and without hypogonadism who received testosterone therapy.
This 2019 guideline update includes a review of new data on anticoagulant use and risk stratification in venous thromboembolism.
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.